Epigenomics Successfully Completes Larger Clinical Study in Early Lung Cancer Detection
Epigenomics AG, a molecular diagnostics company focusing on the development and commercialization of products for cancer detection based on DNA methylation, today announced that it successfully completed a larger clinical study in its lung cancer program. The study was run in close collaboration with Prof. Dr. Christian Witt and Dr. Bernd Schmidt at the Charite University Hospital in Berlin, Germany.
This entry was posted on Wednesday, June 18th, 2008 at 3:13 pm and is filed under Research. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.